Abstract | More than 60 years ago, the effect whereby radiotherapy at one site may lead to regression of metastatic cancer at distant sites that are not irradiated was described and called the abscopal effect (from 'ab scopus', that is, away from the target). The abscopal effect has been connected to mechanisms involving the immune system. However, the effect is rare because at the time of treatment, established immune-tolerance mechanisms may hamper the development of sufficiently robust abscopal responses. Today, the growing consensus is that combining radiotherapy with immunotherapy provides an opportunity to boost abscopal response rates, extending the use of radiotherapy to treatment of both local and metastatic disease. In this Opinion article, we review evidence for this growing consensus and highlight emerging limitations to boosting the abscopal effect using immunotherapy. This is followed by a perspective on current and potential cross-disciplinary approaches, including the use of smart materials to address these limitations. NATURE REVIEWS | CANCER VOLUME 18 | MAY 2018 | 313 PERSPECTIVES © 2 0 1 8 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
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. However, radiotherapy is limited by normal tissue toxicity, and it is generally prescribed for treatment of localized tumours. Recent technological advances have focused on addressing the toxicity limitation, with advanced radiotherapy modalities aimed at achieving greater therapeutic effectiveness (that is, greater tumour cell killing with less normal tissue toxicity and less time under treatment compared with previous approaches) 2, 3 . These advanced radiotherapy technologies and approaches include intensity-modulated radiation therapy (IMRT), image-guided radiotherapy (IGRT), high dose rate (HDR) brachytherapy, stereotactic ablative body radiotherapy (SABR), proton therapy and carbon ion radiotherapy.
For example, IMRT allows the creation and delivery of precise radiation doses that conform to the target tumour while minimizing the dose delivered to neighbouring healthy tissues 2 . The increase advanced modality where a concentrated dose of radiotherapy is administered to a tumour bed during surgery to kill any residual cancer cells after the tumour has been removed 4 . In addition to advanced external beam radiotherapy modalities, HDR brachytherapy has been developed to allow short-distance radiotherapy of cancers, including skin, cervical, prostate and breast cancers, with minimal toxicities to healthy tissue. With these remarkable developments, radiotherapy can currently provide benefit in the treatment of over 50% of patients with cancer when used alone or in combination with other treatments such as surgery (for example, intra-operative radiotherapy) or chemotherapy (chemoradiotherapy) 1 . While advances in radiotherapy technologies have largely focused on minimizing toxicity and improving the therapeutic ratio when treating localized tumours, there have also been recent developments relevant to the abscopal effect that provide a promising frontier in extending the use of radiotherapy to treatment of both localized and metastatic disease. The term 'abscopal' was first introduced in 1953 by Mole 5, 6 to describe an immune-mediated response to radiation by tumour cells located distant from the irradiated site [5] [6] [7] [8] . Over the years, the rare abscopal effect has been reported for several cancers, including melanoma 9 , renal cell carcinoma 10 , breast cancer 7 , hepatocellular carcinoma 11 and other metastatic solid tumours 12 . A recent review estimates that there have been 46 case reports of the abscopal effect from radiotherapy alone between 1969 and 2014 (REF. 13 ).
There is now a growing consensus from many studies indicating that combining radiotherapy with immunotherapy provides an opportunity to boost abscopal response rates. This Opinion article examines the growing evidence behind this consensus and discusses some of the emerging limitations, as many institutions worldwide are increasingly testing this combination strategy. This is followed by a perspective on current and potential cross-disciplinary approaches, including the use of smart biomaterials to address these limitations and extend this benefit to more patients. in conformality and tighter treatment margins engendered an increased need for accuracy to circumvent the potential to miss the tumour owing to organ motion and/or variability in patient setup. IGRT works to assuage this need by allowing imaging of the target immediately before or even during treatment to guide a more geographically precise delivery of the dose 2 . Improved accuracy and greater understanding of radiation biology have in turn made dose escalation feasible, and this has allowed for further improvement in the therapeutic ratio for several tumour sites. The advent of SABR is partly a consequence of this, allowing for hypofractionated treatment with precise delivery of very high radiotherapy doses with short overall treatment times. Other advanced radiotherapy approaches employ high-energy protons or carbon ion beams. The main advantage of therapy with such charged particle beams is the ability to more precisely localize the radiation dosage 4 .
Intra-operative radiotherapy is another
Boosting the abscopal effect Following the first description of the abscopal effect 5 , initial case reports were recorded for melanoma and papillary adenocarcinoma when using radiotherapy alone in 1973 -1975 (FIG. 1) . In 1979, it was shown that cell killing by ionizing radiation contains an immune-mediated component, with the degree of integrity of the host immune system determining the radiosensitivity of a tumour 16 . In a syngeneic mouse model of fibrosarcoma, the radiotherapy dose required to control tumour growth was determined in mice that were T cell competent compared with those that were T cell depleted. It was found that the average radiation dose required to control tumour growth in 50% of the mice was lower for the T cell-competent mice than for the T cell-deficient mice. In addition, the likelihood of developing metastasis in T cell-deficient mice was increased, demonstrating an association between immune status, local response to radiotherapy and metastasis.
Since then, several studies have demonstrated that there is a direct connection between the abscopal effect and mechanisms involving the immune system [17] [18] [19] . For example, in a bilateral syngeneic mouse model of breast cancer, treatment with a combination of radiotherapy on one flank and systemic delivery of the immunoadjuvant FMS-like tyrosine kinase receptor 3 ligand (FLT3L) led to a significant growth delay of the irradiated tumour as well as the non-irradiated tumour compared with untreated control mice. This abscopal effect was dependent on the presence of T cells 17 , suggesting that radiotherapy can increase the immunogenicity of a tumour and hence can be used to improve immunotherapy effectiveness or vice versa. Regarding the latter, results indicating tumour and metastatic disease 28 (FIG. 2) .
Irradiated tumour cells may also release cellular danger-associated molecular patterns (DAMPs) and cytokines that enhance traffic of immune cells 29 . Collectively, these events promote tumour cell elimination by primed CD8 + T cells 30, 31 . The rarity of the abscopal effect suggests that even primed antitumour CD8 + T cells are unable to overcome the suppressive effect of the tumour microenvironment 29, 30 . Immunosuppressive cytokines released by tumours, such as transforming growth factor-β (TGFβ), and surface receptors expressed on T cells, such as CTLA4, can inhibit the function of T cells. M2 macrophages, myeloid-derived suppressor cells (MDSCs) and immature dendritic cells (DCs) may also suppress T cell functions 29, 30 . Tumour elimination could be further inhibited by CD4 + T cells with regulatory function (also called regulatory T (T reg ) cells).
For a range of tumour types, preclinical studies (TABLE 1) consistently show that combining radiotherapy with immunotherapy substantially improves abscopal response rates compared with using radiotherapy or immunotherapy alone. From these studies, it is also evident that different immunotherapeutic agents can boost abscopal responses by targeting different aspects of the immune-mediated response 9, 17, 27 . For example, FLT3L can be used to recruit and stimulate APCs 17, 18, 32 , anti-CD40 can be employed to increase activation of APCs 33 , and anti-CTLA4 or antibodies against programmed cell death protein 1 (PD1) can act as immune checkpoint inhibitors, increasing the T cell activity directed against tumour cells 23, 26, 34 .
Abscopal response factors.
Preclinical studies indicate that appropriate timing, dosage and combinations are likely crucial that the use of immunotherapy could help in boosting the abscopal effect during radiotherapy were reported by a number of preclinical studies [20] [21] [22] [23] [24] [25] (TABLE 1) . These studies also examined different schedules for fractionation and dosing as well as different combinations of radiotherapy and immunotherapy.
In a clinical trial that tested radiotherapy in combination with an immunoadjuvant, granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of multiple types of confirmed solid metastatic cancer, an abscopal response occurred in approximately 30% of patients 12 . In a different study on melanoma, radiotherapy in combination with an immunotherapy comprising antibodies against cytotoxic T lymphocyte-associated antigen (CTLA4) and programmed cell death 1 ligand 1 (PDL1) increased abscopal response rates 26 . Currently, many ongoing studies are investigating the combination of radiotherapy and immunotherapy to improve treatment outcomes for different indications 27 . Abscopal response mechanism. Although the biological mechanism underlying the abscopal effect is yet to be fully understood, several studies have helped to elucidate how combining radiotherapy with immunotherapy would boost this effect. When a tumour is irradiated, the cellular stress or injury in the tumours may lead to the liberation of neoantigens, here referred to as tumour-associated antigens (TAAs), in the context of necrotic and apoptotic tumour cells and debris. A substantial increase in the number and diversity of TAAs can stimulate a tumour-specific immune response, with TAAs engulfed by antigenpresenting cells (APCs) and then presented to CD8 + T cells. The CD8 + T cells can then recognize and attack both the primary Nature Reviews | Cancer First description of the rare AE 5 First insight into the contribution of the immune-mediated component of cell killing by ionizing radiation 16 First case reports of AE for melanoma and papillary adenocarcinoma 14, 15 Study shows that the AE may depend on the fractionation schedule 23 First clinical trial designed to boost the AE with immunoadjuvants 12 Ongoing investigation of the use of immunoadjuvants to boost the AE 27 First evidence of the AE as an immune-driven phenomenon Patient with melanoma shows surprising AE after local radiotherapy in combination with ipilimumab 9 Optimal response in melanoma benefits from radiation combined with immunoadjuvants (anti-CTLA4 and anti-PDL1) to the success of combining radiotherapy and immunotherapy. Many studies have reported substantial abscopal responses when administering immunotherapy after radiotherapy 17, 18, [20] [21] [22] [23] [24] [25] [26] [33] [34] [35] [36] [37] [38] [39] [40] . However, the in response to anti-CTLA4; meanwhile, in another study using the syngeneic mammary carcinoma 4T1 model, anti-CTLA4 administered after radiotherapy generated substantial abscopal responses 20 . Most optimal timing is not clear. In one study on colorectal carcinoma, anti-CTLA4 was effective in generating abscopal responses when given before radiotherapy 36 , which is explained by the depletion of T reg cells On the basis of the preclinical studies (TABLE 1) , the optimal dosing and fractionation strategy for each cancer type has not been determined yet, as both single and fractionated radiotherapy doses have been reported to boost abscopal responses when combined with different immunotherapies 23, 34, 41 . For example, a preclinical study combining radiotherapy with anti-CTLA4 for breast and colon cancer models concluded that 3 fractions of 8 Gy and 5 fractions of 6 Gy are superior to a single ablative dose of 20 Gy (REF. 23 ). However, other work in breast and colon cancer models has also shown synergy when using a single fraction of radiotherapy with other immunotherapies 18, 25, 26, 33, 34, 36, 39, 40, 42, 43 . Multiple preclinical studies have investigated different dose and fractionation regimens in colon cancer (MC38 and colon26) 23, 42 , breast cancer (TUBO, 67NR, TSA and FM3A) 17, 23, 34, 40 , squamous cell carcinoma (SCCVII) 21 , sarcoma (MethA) 42 tumours in patients and the untreated control tumours on the other flank of the animals represented metastasis 17, [20] [21] [22] [23] 26, [33] [34] [35] [36] [37] [38] . Clearly, these subcutaneous tumours are a limited recapitulation of the tumour microenvironments of primary and metastatic tumours in patients. Still, these studies have advanced the understanding of the abscopal effect, and some results have been confirmed in clinical trials. For example, in one recent study 26 , patients with melanoma received hypofractionated radiotherapy targeting a single index lesion, in combination with systemic delivery of anti-CTLA4. When unirradiated lesions were analysed, this treatment showed a partial response as best response in 18% of the patients. When mice with bilateral subcutaneous melanoma tumours received radiotherapy on one flank and systemic delivery of anti-CTLA4, a response rate of about 17% was observed in unirradiated tumours of the other flank, consistent with the clinical trial outcomes. Nevertheless, relatively higher rates of abscopal response or efficacy in mice treated with the combination therapy compared with single-therapy-treated mice or untreated controls observed in many other preclinical studies 17, 23, 33, [40] [41] [42] have not been confirmed in and large-cell lung carcinoma 42 . Generally larger doses per fraction were associated with abscopal effects. An optimal dose range is likely to exist, below which immune stimulation might be suboptimal and above which immunosuppression prevails 44 . Seminal studies using breast cancer models showed that the DNA exonuclease 3ʹ repair exonuclease 1 (TREX1) inhibits immune activation 45, 46 . TREX1 is induced by radiation doses above 12-18 Gy in different colorectal carcinoma and breast cancer cell lines, and it attenuates immunogenicity by degrading double-strand DNA that accumulates in the cytosol upon radiation 47 . Further investigations of dosage and combinations of radiotherapy with immunotherapy are needed to determine the optimal thresholds or range 48 . Currently, a wide range of dose and fractionation schedules is being utilized in clinical studies of metastatic tumours. A recent review highlights the ongoing clinical trials testing these different combinations of radiotherapy with immunotherapy 27 . Many studies investigating the abscopal effect have used bilateral subcutaneous tumour mouse models, in which the treated tumours on one flank of the animals represented primary Nature Reviews | Cancer Limitations A number of limitations have emerged from the available experimental and clinical data testing the combination of radiotherapy and immunotherapy. One obvious limitation is the prevailing lack of sufficient understanding of the mechanism underlying the abscopal effect. A greater understanding is needed to best leverage the abscopal effect and benefit a larger proportion of patients.
Immunosuppression. Even when combining radiotherapy with immunotherapy, the development of a robust abscopal response can still be stifled by the widespread presence of immunosuppression or tolerance at tumour sites. Low immunogenicity of tumour antigens at the local site of irradiation and the prevalence of immunosuppressive cells (for example, MDSCs and T reg cells) and/or of immunosuppressive cytokines (for example, interleukin-10 (IL-10) and TGFβ) work together to limit the abscopal response elicited even by combination approaches. An excellent example of this is a recent study in melanoma combining radiotherapy with anti-CTLA4 that led to a limited abscopal effect, as described above 26 . This study found that radiotherapy and anti-CTLA4 led to upregulation of PDL1 on tumour cells, mediating T cell exhaustion and explaining at least in part the limited abscopal responses observed. Immune-mediated abscopal effects are also likely to be affected by such factors as the patient's degree of myelosuppression, overall tumour burden and the neutrophil:lymphocyte ratio in addition to the patient's prior exposure to radiotherapy or cytotoxic chemotherapy 27 . The depletion of immune cells, or lymphopaenia, observed in most patients with cancer is likely to decrease the chances of an effective immune response. Hypoxic regions within tumours can also contribute to immunosuppression 50 . For example, chemokines induced by tumourassociated hypoxia enable recruitment of immunosuppressive T reg cells, as shown in ovarian cancer 51 . Hypoxia is also known to alter the capacity of APCs in antigen presentation and can make tumour cells more resistant to T cell-mediated killing, as shown in a murine model of breast cancer 52 . In general, any factors that suppress the immune system may hamper the development of robust abscopal responses. this immunosuppression 26 . The study showed that radiotherapy increases the diversity of the T cell receptor repertoire of intratumoural T cells and that anti-CTLA4 inhibits immunosuppressive T reg cells, while the addition of PDL1 blockade reverses T cell exhaustion to mitigate the decrease in the CD8 + T cell:T reg cell ratio and further encourage oligoclonal T cell expansion. Hence, radiotherapy combined with immunotherapeutic agents that have different mechanisms of action might boost abscopal response rates.
Intratumoural administration of immunotherapeutic agents in combination with radiotherapy has been shown to be effective in overcoming immunosuppression in lymphoma 60, 61 . This is particularly relevant when using immunotherapies that target specific immune cells within the tumour microenvironment; hence, it may be preferable to deliver these agents locally into the tumour rather than systemically. Local delivery of the immunotherapeutic agent allows for much higher or more potent concentrations in the tumour microenvironment than via systemic delivery. In one example of intratumoural delivery, toll-like receptor (TLR) agonists were administered to generate potent abscopal responses in combination with low-dose radiotherapy 62 . In particular, 15 patients with non-Hodgkin lymphoma were treated with radiotherapy (2 × 2 Gy) at a single site with concomitant intratumoural administration of 6 mg synthetic CpG oligodeoxynucleotides, which act as a TLR9 agonist. The results after 12 weeks showed objective abscopal responses at distant non-treated sites in 4 of the 15 patients 62 .
Strategies that can minimize hypoxia in the tumour microenvironment could also help overcome immunosuppression and radioresistance. For example, hypoxiainducible factor modulators such as dimethyloxalylglycine (DMOG) 63 can inhibit immunosuppressive hypoxic signalling 50, 63 . Furthermore, the use of charged particle radiotherapy might promote uniform cell killing in tumours that have heterogeneous radiosensitivity as a result of intermittent normoxic and hypoxic regions within the tumour. This approach takes advantage of high linear energy transfer (LET), which uses dense ionization tracks that inflict direct DNA damage, showing high biological effectiveness because of less dependency on oxygenation of tissues 64 . Increased generation of neoantigens by higher LET radiation may also increase the potential for generating an abscopal response.
Toxicities. While rational combinations of radiotherapy and immunotherapy could overcome immunosuppression and lead to vigorous antitumour T cell responses 14, 18 , the systemic and overlapping toxicities from such a combination could be a substantial obstacle 30, 53 . Immune-related adverse events that can be severe or lifethreatening have been seen following treatment with immunomodulatory agents such as ipilimumab and anti-PD1 antibodies 53, 54 . Combining radiotherapy with immunotherapy, which affects different steps in the immune response, might increase the likelihood of these adverse events 48 . Immune-related adverse events of concern include dermatological, gastrointestinal, hepatic, endocrine and other, less common inflammatory events 55 . For example, early studies combining radiotherapy with interferon-α (IFNα) in pancreatic cancer were promising 56 , but the phase II trial showed unacceptably high rates of toxicity using this treatment 57 . Unfortunately, preclinical studies investigating toxicities do not adequately predict the range of pathology that is observed in humans. For example, hypophysitis, a somewhat common side effect of ipilimumab, was not anticipated from experimental studies in mouse models 48, 49 . Initial clinical experience suggests that routine palliative radiotherapy is likely to be well tolerated in the setting of anti-CTLA4 and anti-PD1 therapy 58 , and ongoing clinical trials for different indications 27 will help provide the needed additional prospective data on toxicities and efficacy.
Overcoming immunosuppression
Strategies under investigation for improving outcomes when combining radiotherapy with immunotherapy include promoting cross-priming of tumour-specific CD8 + T cells, stimulating the immune effector function of T cells primed by radiotherapy and neutralizing the immunosuppressive effects of the tumour microenvironment 30 . Ongoing studies are investigating optimal timing, dosage and combinations with different immunotherapeutic agents relevant to these strategies 26, 27, 47, 59 . As an example, an approach to overcome immunosuppression is to use multiple immunotherapeutic agents, as highlighted in a recent melanoma study describing PDL1-mediated immunosuppression when tumours were treated with a combination of radiotherapy and anti-CTLA4, as described above, and employing a combination of anti-CTLA4 and anti-PDL1 to overcome Most reported cases of the abscopal effect occur in immunogenic tumours 7, 9, 65, 66 . A high level of tumour immunogenicity is important for favourable treatment outcomes, and treatment strategies should focus on developing combination therapies that increase immunogenicity through increasing immunogenic cancer cell death [67] [68] [69] . Such strategies aim at inducing a specific level of cell death that can generate sufficient neoantigens, and specific danger signals, to help overcome the condition of local immunosuppression which is characteristic of established tumours 70 . Studies indicate that tumour immunogenicity may be increased by the use of protons or carbon ion radiotherapy and α-particles, which are considered to have high LET 71 . The combination of radiotherapy with anticancer vaccines and checkpoint inhibitors has been shown to overcome immunosuppression and to increase response rates in preclinical models 72 . For example, a promising strategy involving sequential combination of radiotherapy, vaccination and anti-PDL1 in a mouse model of pancreatic cancer converts non-T-cell-inflamed cancers into T cell-inflamed cancers and mediates regression of established pancreatic tumours 72 .
Other groups are also investigating the use of irradiated tumour cell vaccines as a strategy to boost therapeutic outcomes [73] [74] [75] . In one such study using a B16 melanoma model 74 , it was shown that irradiated tumour cells that were genetically modified to express murine GM-CSF stimulated potent, long-lasting and
In another study using a mouse model of melanoma, nanoparticles were used to deliver CTLA4-targeting small interfering RNA (siCTLA4) into T cells at tumour sites, resulting in increased T-cell mediated antitumour immune responses in mice receiving siCTLA4-loaded nanoparticles compared with melanoma-bearing mice receiving control nanoparticles 79 . The combination of this therapy with radiotherapy promises to boost the abscopal effect more effectively.
High-atomic-number nanoparticles such as gold nanoparticles may also be employed to increase tumour immunogenicity by leveraging the photoelectric effect, in which radiation can induce the emission of micrometre-range photoelectrons and Auger electrons 2 . These Auger electrons have high LET and the potential to inflict more irreparable mutations upon tumour cell DNA, which could help by increasing tumour immunogenicity or overcoming immunosuppressive hypoxia 2, 80, 81 . A merit of using nanoparticles is that they could also serve as imaging contrast agents, which could be valuable in image-guided drug delivery of immunotherapy to boost the abscopal effect. Nanoparticles such as gadolinium nanoparticles have the potential to improve radiotherapy 82, 83 but also provide magnetic resonance imaging (MRI) contrast, which would resonate with recent IGRT developments towards MRI-guided radiotherapy 82, 84, 85 . The use of nanoparticles with image contrast capability could also facilitate non-invasive monitoring of the effect of radiotherapy and immunotherapy combinations on tumour progression, as shown in recent studies, with nanoparticles designed to allow tracking of cancer-specific T cells in vivo 86, 87 . The use of SRBs 76 for sustained delivery of immunotherapeutic payloads could also help overcome immunosuppression, especially given the persistent and contemporaneous presence of antigen and adjuvant signalling in the tumour microenvironment, which may not be attainable in the case of intratumoural delivery of immunotherapy that can diffuse away fairly rapidly. The advantage of a sustained delivery is predicated on promising results from vaccine studies, which have shown that sustained delivery of a vaccine using biomaterials elicits increased proliferation of antigen-specific CD8 + T cells compared with the effect elicited by delivery of the same vaccine through injections Using smart materials technologies. Smart materials technologies, including nanoparticles and smart radiotherapy biomaterials (SRBs) 76 , provide great opportunities to address the above limitations to priming the abscopal effect
. There are a number of reasons why smart materials may help overcome immunosuppression.
Targeted nanoparticles could be loaded with potent immunotherapeutic payloads that can be delivered controllably or sustainably during radiotherapy to prime abscopal responses more efficaciously, overcoming immunosuppression. A recent review highlights studies showing that the use of nanoparticles to deliver immunotherapy can boost antitumour immune responses 77 .
In one study using a mouse model of melanoma, targeted delivery of CpG oligodeoxynucleotides by nanoparticles to DCs in the draining lymph node increased the CD8 + T cell:T reg cell ratio, delaying tumour growth compared with mice receiving immune adjuvant-free nanoparticles 78 .
Box 1 | Smart materials technologies for boosting the abscopal effect
Contemporaneous developments in smart materials technologies offer potential solutions for addressing limitations of immunosuppression and toxicity. Smart materials 76 are designed to be sensitive to specific stimuli (for example, tumour microenvironment, pH, the wavelength or intensity of incident radiation or an electrical or magnetic field) and to then respond in active ways, including changing their structure for drug delivery, priming an immune response or other functions that have the potential to cogently improve treatment outcomes. Examples of smart materials technologies worth consideration, with perspective on boosting the abscopal effect with minimal toxicities, include nanoparticles and smart radiotherapy biomaterials (SRBs) 2, 76, 108 . One distinctive feature of nanoparticles highlighted in oncological applications is their potential for improving the therapeutic index of a drug by increasing effectiveness and/or reducing toxicities (reviewed in REF. 108 ).
Beside nanoparticles, it has been proposed that currently used inert radiotherapy biomaterials (fiducials, spacers, beacons, and so on) can be replaced with SRBs loaded with drugs for therapy modulation 76, 109 . The currently used inert radiotherapy biomaterials have only one function, which is to ensure geometric accuracy during treatment 109 . They could be replaced with multifunctional SRBs, which provide geometric accuracy but can also deliver drug payloads 110 . Currently proposed SRB designs incorporate smart polymer components 76, 111, 112 that can sense and actuate or change structure to release payloads incorporated in their polymer matrix in a controlled way. Following implantation, as currently done for inert radiotherapy biomaterials, the SRBs can be activated by the tumour microenvironment or other stimuli to sustainably release the payloads in situ and directly into the tumour (FIG. 2) . During radiotherapy, antigens from the dying tumour cells could serve as an in situ vaccine, working in conjunction with the released immunotherapeutic agent to potentiate the immune-mediated abscopal effect.
carcinoma-tumour-bearing mice treated with radiotherapy in combination with anti-CD40 delivered through SRBs compared with mice receiving radiotherapy in combination with anti-CD40 delivered through injections (W.N., O.C.I. and J.D.S., unpublished observations). Besides this, the use of SRBs for sustained in situ delivery of payloads is a relatively more convenient way to deliver immunotherapeutic agents than repeated intratumoural injections 49 . Another merit of using SRBs is that the use of polymers such as poly(lactic-co-glycolicacid) (PLGA) or chitosan as components of these SRBs could itself have a major effect in priming an immune response. Recent studies 89, 90 have shown that these particular polymers, used in prototype SRBs 76 , support the maturation of DCs. Studies also showed that DCs treated with PLGA and chitosan films supported higher levels of T cell proliferation than control DCs [91] [92] [93] . In parallel, biomaterials have been shown to increase the immunogenicity of antigens. For example, adsorption of ovalbumin to PLGA scaffolds has been found to support antibody-mediated immune responses [94] [95] [96] . Taken together, there is compelling evidence from these studies that intelligently engineered SRBs may engender pro-immunogenic activity, which would be helpful in overcoming the commonly encountered local immunosuppression of established tumours.
Minimizing toxicities Dose optimization and focused delivery.
To minimize toxicities when combining radiotherapy and immunotherapy, a standard strategy is to use as low as reasonably possible doses of radiotherapy and immunotherapy that would engender optimal therapeutic outcomes. With respect to radiotherapy, retrospective studies highlight that conformal radiation dose delivery, with the radiotherapy beam shaped to tightly conform to the tumour margins, is crucial for minimizing toxicity 53, 97 . The use of advanced conformal radiotherapy treatment modalities such as IMRT, SABR or proton therapy would allow for substantial reductions in radiation toxicity. HDR brachytherapy or short-distance radiotherapy, which brings radioactive sources close to tumour tissue, is specifically designed to reduce toxicity to neighbouring healthy tissue. A recent study on colorectal carcinoma has shown that HDR brachytherapy combined with anti-PD1 or anti-CD137 monoclonal antibodies engendered abscopal responses 35 . Thus, such a combination approach could also be further developed with potential to minimize toxicity. antibodies has been blocked by dose-limiting toxicities 100 . CD40 is expressed by B cells, macrophages and DCs throughout the body, and systemic administration leads to immune-related adverse events, such as cytokine release syndrome and liver toxicity. An agonistic anti-CD40 antibody delivery system based on a slow-release agent would cause fewer side effects than systemic therapy 99, 100 . SRB delivery systems offer great promise in the context of combining radiotherapy with immunotherapy.
Biomarkers
Studies designed to monitor different biomarkers should also provide valuable information to improve our understanding of boosting abscopal responses. Validated biomarkers could help inform patient selection, monitor treatment response or help identify optimal treatment strategies to overcome immunosuppression with minimal toxicities. Studies investigating the combination of radiotherapy and immunotherapy could introduce biomarkers (for example, measurement of tumourassociated macrophages, MDSCs and T reg cells) to facilitate the design and fine-tuning of approaches. For example, recent preclinical evidence suggests that TREX1 induction could guide the selection of optimal radiation dose and fractionation in patients treated with radiotherapy and immunotherapy 47 . Because determining the optimal dose or BED includes comparison of the rates of tumour cell killing for different fractionations or schedules in radiotherapy, it also informs what timing or schedules are best in generating an abscopal effect. A recent review 44 supports the use of SABR treatment schedules. Machine learning and modelling applied to data from clinical trials 27 could shed further light on the optimal BED and timing for different tumour tissue types.
TABLE 2 summarizes the merits and demerits of different approaches that have been discussed for boosting the abscopal effect. Evidently, studies that will continue to advance mechanistic understanding of the abscopal effect will avail efforts in developing these approaches. Besides the understanding that T cells are required to mediate the abscopal effect during radiotherapy 17 , cytokine release has been suggested as another mechanism to mediate the abscopal effect 101 . This has been supported by the fact that the production of tumour necrosis factor in the irradiated tumour microenvironment in mice can reduce the number of immunosuppressive MDSCs 34 .
With respect to immunotherapy, the route of administration is crucial in determining toxicity. A major rationale for the approach of intratumoural delivery is that it can allow for reduction of systemic toxicity. This approach is supported by results from different studies 60, 61 . As already mentioned, intratumoural administration of an escalated dose of CpG oligodeoxynucleotides in combination with low-dose radiotherapy was well tolerated in a trial of patients with follicular lymphoma 61 . In another study, intratumoural administration of ipilimumab at one-hundredth of the systemic dose was found to be active, safe and well tolerated in lymphoma 60, 98 . These studies indicate that the relative safety of intratumoural therapies offers advantages as we move into a future with increasing combination therapies. An acknowledged limitation of the intratumoural therapy approach is that it is limited to specific, accessible tumour types where direct intratumoural administration of the immunotherapy is feasible. Overall, more studies investigating the optimal dosing or scheduling to optimize both radiotherapy and immunotherapy dose and manner of administration are needed.
Delivery through smart materials. It has been demonstrated that the use of targeted biocompatible gold nanoparticles loaded with immunotherapeutic agents can improve the delivery and safety of immunotherapy 77 .
The use of such high-atomic-number nanoparticles could also avail efforts to minimize radiation toxicity 2 . Radiationinduced photoelectrons and Auger electrons can substantially boost local damage to tumour cells, allowing a reduction in the dose or number of fractions of primary radiation to be administered. As such, this could minimize radiation toxicity to normal tissues and/or lymphopaenia. Reducing the number of treatment fractions could also help improve patients' compliance and reduce the financial cost of treatments. Besides gold nanoparticles, platinum-based chemotherapy drugs (for example, cisplatin or carboplatin) loaded on nanoparticles could also provide a multi-pronged approach for combining chemoradiotherapy with immunotherapy, potentially resulting in more potent local and metastatic tumour cell killing with reduced toxicities.
An advantage of using SRBs is that the direct and sustained delivery of the respective immunotherapeutic agent has potential to substantially minimize systemic or overlapping toxicities 99 . For example, the clinical use of agonistic anti-CD40
Another potential marker predictive of response to immunotherapy and radiotherapy is the induction of calreticulin. Sublethal radiation exposure of tumour cells enhanced antigen processing and increased calreticulin expression on human breast, lung and prostate carcinoma cells compared with untreated control cells 102 . In these different carcinoma types, tumour cells that had been exposed to radiotherapy were significantly more sensitive to T cell killing, suggesting that the increased T cell killing is a consequence of direct interaction of the exposed calreticulin with T cells. It was also reported that knockdown or depletion of calreticulin in cancer cells resulted in decreased T cell killing of calreticulin-deficient cancer cells compared with control cells 102 .
The promise of intratumoural therapy
The preclinical studies in TABLE 1 employ subcutaneous tumours in mice as the primary site and report positive abscopal responses. These outcomes suggest that subcutaneous tumours can be treated with radiotherapy and immunotherapy to modulate robust abscopal responses that can inhibit tumour growth or metastatic progression in distant untreated sites, and they offer a strategy in which subcutaneous tumours or metastasis in patients could be targeted as the primary site to prime or modulate a robust abscopal great motivation for more cross-disciplinary research, which can leverage these discoveries to address current limitations and boost the application of radiotherapy to the treatment of both local and metastatic disease. Metastasis accounts for over 90% of cancer-related death and suffering [105] [106] [107] . Hence, boosting radiation-induced abscopal response rates could substantially impact patient care far beyond the patients who now benefit from radiotherapy or immunotherapy alone. Overall, there is a considerable impetus for more concerted research collaborations combining radiotherapy and immunotherapy with smart materials science in boosting the abscopal effect, thereby improving patient outcomes and saving more lives. response. Such patients may then benefit from the advantages of intratumoural delivery or use of SRBs whose main limitation is access to the primary tumour site. A substantial number of patients with cancer with cutaneous metastasis could benefit from such a subcutaneous modulation approach. In one retrospective study of 7,316 patients covering a range of tumour types, 367 patients (5%) showed incidence of cutaneous metastasis 103 .
In another study 104 , 1,080 patients out of 20,380 patients with a range of cancer types had cutaneous metastasis. Given the potential benefit, such a therapy approach is worth further investigation, using animal models with both subcutaneous tumours and orthotopic tumours with metastasis.
Conclusions
Many decades after the rare abscopal effect was first described, research developments provide increasing evidence that the use of radiotherapy with immunotherapy could boost the abscopal effect. Persisting challenges in overcoming established cancer immunosuppression and mitigating dose-limiting toxicities remain. Many studies are ongoing to address these limitations and to better understand how to optimize combinations of radiotherapy and immunotherapy. With parallel developments in smart materials technologies, there is 
